Polymer conjugates of opioid antagonists

Details Polymer conjugates of opioid antagonists Polymer conjugates of opioid antagonists

2006-01-17

2010-02-16

Silverman, Eric E. (Department: 1618)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Aftertreated polymer

C424S078260, C424S078270

Reexamination Certificate

active

07662365

ABSTRACT:
The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.

REFERENCES:
patent: 4366159 (1982-12-01), Magruder et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4719215 (1988-01-01), Goldberg
patent: 4730048 (1988-03-01), Portoghese
patent: 4806556 (1989-02-01), Portoghese
patent: 4861781 (1989-08-01), Goldberg
patent: 5053228 (1991-10-01), Mori et al.
patent: 5102887 (1992-04-01), Goldberg
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5225206 (1993-07-01), Fushimi et al.
patent: 5250542 (1993-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5434171 (1995-07-01), Frank et al.
patent: 5567422 (1996-10-01), Greenwald
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5866164 (1999-02-01), Kuczynski et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6419959 (2002-07-01), Walter et al.
patent: 6451806 (2002-09-01), Farrar
patent: 6515100 (2003-02-01), Harris
patent: 6703381 (2004-03-01), Ekwuribe et al.
patent: 2002/0182172 (2002-12-01), Bentley et al.
patent: 2003/0044402 (2003-03-01), Nelson
patent: 2003/0105275 (2003-06-01), Bentley et al.
patent: 2004/0023852 (2004-02-01), Roberts et al.
patent: 2005/0136031 (2005-06-01), Bentley et al.
patent: 2006/0182692 (2006-08-01), Fishburn et al.
patent: 2009/0221766 (2009-09-01), Cheng et al.
patent: 0995757 (2000-04-01), None
patent: WO 93/24476 (1993-12-01), None
patent: WO 96/21469 (1996-07-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 01/19407 (2001-03-01), None
patent: WO 01/47562 (2001-07-01), None
patent: WO 01/62299 (2001-08-01), None
patent: WO 02/065988 (2002-08-01), None
patent: WO 02/089789 (2002-11-01), None
patent: WO 03/032990 (2003-04-01), None
patent: WO 03/037384 (2003-05-01), None
patent: WO 03/037385 (2003-05-01), None
patent: WO 03/051113 (2003-06-01), None
patent: WO 03/079972 (2003-10-01), None
patent: WO 03/101476 (2003-12-01), None
patent: WO 2004/082620 (2004-09-01), None
Chemicalland21 disclosure “2′-Deoxycytidine” Downloaded from the world wide web on Dec. 22, 2006.
Penn, N.W. “Deoxycytidine: a morphine antagonist” Arch Intl Pharmacodyn Ther May 1978;233(1):145-55.
Asai et al., “Naloxone Inhibits Gastric Emptying in the Rat”,Anesth. Analg., 1999, pp. 204-208, vol. 88.
Batz et al., “Pharmacologicaly Active Polymers 9thReport: Retard Forms of Morphine Antagonists”,Arzneimittel-Forshung, 1997, pp. 1884-1888, vol. 27 (ii), No. 10.
Bennett et al., “Biodegradable Polymeric Prodrugs of Naltrexone”,Journal of Controlled Release, 1991, pp. 43-52, vol. 16, Nos. 1/2.
Bennett et al., “Drug-Coupled Poly(Amino Acids) as Polymeric Prodrugs”,Journal of Bioactive and Compatible Polymers, 1988, pp. 44-52, vol. 3.
Fishman, J., et al., “Preparation and Evaluation of a Sustained Naloxone Delivery System in Rats,”Pharmacology, 1975, pp. 513-519, vol. 13(6).
Greenwald, R., et al., “Highly Water Soluble Taxol Derivatives: 7-Polyethylene Glycol Carbamates and Carbonates,”J. Org. Chem., 1995, pp. 331-336, vol. 60.
Harris, J. M., ed., “Poly(Ethylene Glycol) Chemistry—Biotechnical and Biomedical Applications,” 1992, pp. 1-10, Plenum Press, New York.
Jiang et al., “Stereochemical Studies on Medicinal Agents. 23.1Synthesis and Biological Evaluation of 6-Amino Derivatives of Naloxone and Naltrexone”,J. Medicinal Chemistry, 1977, pp. 1100-1103, vol. 20, No. 8.
Johansson et al., “Effect of some poly(ethylene glycol)-bound and dextran-bound affinity ligands on the partition of synaptic membranes in aqueous two-phase systems”,J. Chromatogr. B, 1994, pp. 137-147, vol. 652.
Lapicque et al., “Polysaccharidic Prodrugs for Enzymatically Controlled Release”,Journal of Controlled Release, 1986, pp. 39-45, vol. 4.
Li et al., “Poly(α-Amino Acid)-Drug Conjugates—A Biodegradable Injectable Drug Delivery System”,Polymer Preprints(American Chemical Society, Division of Polymer Chemistry). 1990, pp. 198-199, vol. 21, No. 2.
Mahkam et al., “Preparation of new biodegradable polyurethanes as a therapeutic agent”,Polymer Degradation and Stability, 2003, pp. 199-202, vol. 80.
Negishi et al., “Coupling of Naltrexone to Biodegradable Poly(α-Amino Acids)”,Pharmaceutical Research, 1987, pp. 305-310, vol. 4, No. 4.
Olde et al., “Affinity Partitioning and Centrifugal Counter-Current Distribution of Membrane-Bound Opiate Receptors Using Naloxone-Poly(Ethylene Glycol)”.,Neuroscience, 1985, pp. 1247-1253, vol. 15, No. 4.
Pasternak et al., “Macromolecular Naloxone: A Novel Long-Acting Polymer-Bound Drug”,Life Sciences, 1976, pp. 977-982, vol. 18.
Sidman et al., “Use of Synthetic Polypeptides in the Preparation of Biodegradable Delivery Systems for Narcotic Antagonists”,Synthetic Polypeptide Systems, 1980, pp. 214-231.
Takahashi, R.N., et al., “Effects of Ketamine on Nociception and Gastrointestinal Motility in Mice Are Unaffected by Naloxone,”pGen. Pharmac., 1987, pp. 201-203, vol. 18(2), Pergamon Journals Ltd.
Yolles, S., et al., “Long Acting Delivery Systems for Narcotic Antagonists II: Release Rates of Naltrexone from Poly(lactic Acid) Composites,”Journal of Pharmaceutical Sciences, Feb. 1975, pp. 348-349, vol. 64(2).
Zalipsky, Samuel., “Chemistry of Polyethylene Glycol Conjugates with Biologically Active Molecules”,Advanced Drug Delivery Reviews, 1995, pp. 157-182, vol. 16.
Zalipsky, S., “Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates,”Bioconjugate Chem., 1995, pp. 150-165, vol. 6, American Chemical Society, USA.
Erez et al., “Narcotic Antagonistic Potency of Bivalent Ligands Which Contain β-Naltrexamine. Evidence for Bridging between Proximal Recognition Sites”,J. Med. Chem., 1982, pp. 847-849, vol. 25, No. 7.
Eldon, et al., “NKTR-118 (Oral PEG-Naloxol), a PEGylated Dervative of Naloxone: Demonstrations of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models,” Poster 28 presented at the American Academy of Pain Management 18thAnnual Clinical Meeting; Sep. 27-30, 2007; Las Vegas, NV.
ISA, International Search Report dated Mar. 28, 2003 for PCT/US02/33325.
ISA, International Search Report and Written Opinion dated Nov. 28, 2005 for PCT/US04/042661.
The Merck Index, 12thEdition (Merck & Co., Inc. Whitehouse Station N.J., 1996), entry 6449, pp. 1092-1093.
Nektar Therapeutics, “Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC),” PRNewswire dated Mar. 2, 2009.
Neumann et al., “Clinical Investigation of NKTR-118 as a Selective Oral Peripheral Opioid Antagonist,” Poster 27 Presented at the American Academy of Pain Management 18thAnnual Clinical Meeting; Sep. 27-30, 2007; Las Vegas, NV.
Yamashita et al., “Micelle Monomer Control over the Membrane-Disrupting Properties of an Amphiphilic Antibiotic”, J. Am. Chern. Soc., 1995; pp. 6249-6253, vol. 117.

Affiliated with

Also associated with

Rating

Polymer conjugates of opioid antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymer conjugates of opioid antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer conjugates of opioid antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4215399